FDA Guidance On ANDA Antibundling Statute Expected In February
Executive Summary
The ANDA bundling and antibundling provisions of the Medicare law will be part of a "short guidance" that FDA expects to issue in February
You may also be interested in...
“Shared Exclusivity” Could Apply To Eight First-Time Generics, FDA Says
At least eight first-time ANDA approvals over the next two years could require a determination of whether 180-day "shared exclusivity" should be awarded, FDA says in a court filing
“Shared Exclusivity” Could Apply To Eight First-Time Generics, FDA Says
At least eight first-time ANDA approvals over the next two years could require a determination of whether 180-day "shared exclusivity" should be awarded, FDA says in a court filing
Paxil Generics On Hold After Court Rejects FDA “Shared Exclusivity” Policy
No more generic versions of GlaxoSmithKline's Paxil will be approved before early March under a court decision rejecting FDA's approach to "shared exclusivity.